(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 December 2022 (08.12.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/253800 A1

(51) International Patent Classification:
A61K 31/502 (2006.01) *A61P 35/04* (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:
PCT/EP2022/064697

(22) International Filing Date:
31 May 2022 (31.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/195,795 02 June 2021 (02.06.2021) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).

(72) Inventor: **FIELDING, Anitra**; AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: METHODS OF TREATING BREAST CANCER

(57) Abstract: This disclosure relates to methods for the adjuvant treatment of a subject having germline mutated BRCA1 and/or BRCA2 breast cancer, wherein the subject has previously received local treatment for the breast cancer, and neoadjuvant or adjuvant chemotherapy.

WO 2022/253800 A1